Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If they can manage to be a safer holding than faster-growing stocks, though, they can still be worthwhile to have in your portfolio, assuming you're looking for dividend cash flow and you're relatively risk-averse.

Viatris (NASDAQ: VTRS) is an up-and-coming generic manufacturer that could have the makings to be a good long-term holding, at least based on its 5.2% dividend. Let's explore whether this healthcare stock can live up to that promise and whether it's worth buying. 

Ideally, an investment in a generic drug manufacturer like Viatris would have (at least) three features:

Continue reading

Source Fool.com